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Identification of new drug targets and the development
of new drugs and therapies for neurological diseases
currently relies on preclinical data generated using in
vitro and in vivo animal models as a prelude to clinical
trials. While this “bench to bedside” approach has
resulted in some successes, it has been notoriously inef-
ficient, largely due to the failure of most preclinical
results to translate to clinical use. Countless new chemi-
cal entities have shown promise in preclinical studies
but have then either failed to demonstrate efficacy in
Phase 2 or Phase 3 clinical trials or have been with-
drawn due to unanticipated side effects or toxicities.
These failures not only limit the availability of new ther-
apeutic options but they can be catastrophically expen-
sive thereby curtailing future research and driving up
the cost of developing new agents. An oft-cited example
is neuroprotection following stroke, wherein literally
thousands of new compounds have shown robust neuro-
protection in animal studies, but to date, none have
translated to a clinically useful compound despite bil-
lions of euros spent.
While it is clear that part of the problem with current
animal models is that the brain of each species is differ-
ent (rats and mice are not humans and vice versa) it is
also my contention that there are fundamental problems
with our historical approach to developing and utilizing
animal models for new drug development. These pro-
blems include:
1. Current animal models reproduce end-stage symp-
toms instead of disease. This means that it is only possi-
ble to test products that mitigate the symptoms that
appear late in the disease process. Creation of animal
models of disease versus symptoms will permit the iden-
tification of early-stage biomarkers and the development
of disease-modifying therapies that can be used pre-
symptomatically to slow or arrest the disease process.
2. Models are simple whereas diseases are complex.
Most preclinical approaches are essentially “reduction-
ist”; looking at only a single brain region or even cell
type. Moreover they are “neurocentric” avoiding the
contribution of other cell types (e.g. glia) and other sys-
tems (e.g. vasculature). They also tend to be “static”
whereas disease progression is “dynamic” and subject to
on-going modification.
3. Most models concentrate on one set of symptoms
associated with one defined disease. In contrast, most neu-
rology patients present with a complex milieu of symp-
toms and co-morbidities that combine features of multiple
diseases. Further, each patient’s presentation is often dif-
ferent, so to progress therapy must move beyond the “one
size fits all” mentality and accordingly animal models must
embrace diversity rather than trying to eliminate it.
This presentation will expand upon these somewhat
provocative ideas and will introduce several examples of
new animal models that are trying to overcome these pro-
blems. Such models are essential if we are to develop new
methodologies and screening techniques that are predic-
tive of disease onset, are aimed at prevention rather than
palliation, and recognize the patient as a person. Equally
important is the need for improved dialogue between clin-
icians and basic scientists so that future preclinical drug
development is based on what disease looks like in the
patient rather than the test-tube.
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